secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLENO THERAPEUTICS INC (SLNO)
CIK:        0001484565
Form:       8-K
Filed at:   2025-10-14T23:59:59+00:00
Accession:  0001193125-25-237854
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soleno Therapeutics appoints Mark W. Hahn to Board and Audit Committee
----------------------------------------------------------------------

- Board increased to 7 seats; Hahn appointed as Class II director, term expiring at 2028 annual meeting.
- Hahn received 10,046 RSUs vesting over 3 years under Outside Director Compensation Policy.
- Hahn most recently was CFO of Verona Pharma through its acquisition by Merck for ~$10B in Oct 2025.
- Previously CFO of Dova Pharma (acquired by Sobi for up to $915M) and Cempra (IPO lead).
- Hahn brings nearly 30 years of CFO-level experience; certified CPA in Maryland and North Carolina.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484565/000119312525237854/0001193125-25-237854-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484565/000119312525237854/d847935d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-237854

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer